Antiaversive effects of cannabinoids: Is the periaqueductal gray involved?

Neural Plasticity

Volumn 2009, Issue , 2009, Pages

  Moreira, F A ^a   Aguiar, A C ^a   Campos, A C ^a   Lisboa, S F ^a   Terzian, A L ^a   Resstel, L B ^a   Guimaraes F S ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ANANDAMIDE; ARACHIDONYL TRIFLUOROMETHYL KETONE; CANNABIDIOL; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CAPSAZEPINE; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DEXANABINOL; DRONABINOL; ENDOCANNABINOID; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; OLVANIL; RIMONABANT; VANILLOID RECEPTOR 1; ANXIOLYTIC AGENT; CAPSAICIN; DRUG DERIVATIVE; TRPV1 PROTEIN, RAT; UNCLASSIFIED DRUG; VANILLOID RECEPTOR;

AMYGDALOID NUCLEUS; ANTINOCICEPTION; ANXIETY; AVERSIVE BEHAVIOR; DOSE RESPONSE; DRUG MECHANISM; EXPLORATORY BEHAVIOR; HIPPOCAMPUS; HUMAN; NEUROTRANSMISSION; NONHUMAN; PERIAQUEDUCTAL GRAY MATTER; PREFRONTAL CORTEX; REVIEW; TRANQUILIZING ACTIVITY; ANIMAL; ARTICLE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; MICROINJECTION; PHYSIOLOGICAL STRESS; PHYSIOLOGY; RAT; SYNAPTIC TRANSMISSION;

ANIMALS; ANTI-ANXIETY AGENTS; CANNABIDIOL; CANNABINOIDS; CAPSAICIN; MICROINJECTIONS; PERIAQUEDUCTAL GRAY; RATS; RECEPTOR, CANNABINOID, CB1; STRESS, PHYSIOLOGICAL; SYNAPTIC TRANSMISSION; TRPV CATION CHANNELS;

EID: 59649115683     PISSN: 20905904     EISSN: None     Source Type: Journal    
DOI: 10.1155/2009/625469     Document Type: Review

References (115)

1. M. Booth, Cannabis: A History, Banton Books, London, UK, 2003.
2. D. T. Courtwright, Forces of Habit: Drugs and the Making of the Modern World, Harvard University Press, Cambridge, Mass, USA, 2001.
3. A. W. Zuardi, "History of cannabis as a medicine: A review," Revista Brasileira de Psiquiatria, vol. 28, no. 2, pp. 153-157, 2006.
4. R. Mechoulam, "Marijuana chemistry," Science, vol. 168, no. 936, pp. 1159-1166, 1970.
5. W. D. M. Paton, "Pharmacology of marijuana," Annual Review of Pharmacology, vol. 15, pp. 191-220, 1975.
6. W. A. Devane, F. A. Dysarz III, M. R. Johnson, L. S. Melvin, and A. C. Howlett, "Determination and characterization of a cannabinoid receptor in rat brain," Molecular Pharmacology, vol. 34, no. 5, pp. 605-613, 1988.
7. L. A. Matsuda, S. J. Lolait, M. J. Brownstein, A. C. Young, and T. I. Bonner, "Structure of a cannabinoid receptor and functional expression of the cloned cDNA," Nature, vol. 346, no. 6284, pp. 561-564, 1990.
8. W. A. Devane, L. Hanus, A. Breuer, et al., "Isolation and structure of a brain constituent that binds to the cannabinoid receptor," Science, vol. 258, no. 5090, pp. 1946-1949, 1992.
9. R. Mechoulam, S. Ben-Shabat, L. Hanus, et al., "Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors," Biochemical Pharmacology, vol. 50, no. 1, pp. 83-90, 1995.
10. S. Munro, K. L. Thomas, and M. Abu-Shaar, "Molecular characterization of a peripheral receptor for cannabinoids," Nature, vol. 365, no. 6441, pp. 61-65, 1993.
11. M. Rinaldi-Carmona, F. Barth, M. Héaulme, et al., "SR141716A, a potent and selective antagonist of the brain cannabinoid receptor," FEBS Letters, vol. 350, no. 2-3, pp. 240-244, 1994.
12. S. J. Gatley, A. N. Gifford, N. D. Volkow, R. Lan, and A. Makriyannis, "123I-labeled AM251: A radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors," European Journal of Pharmacology, vol. 307, no. 3, pp. 331-338, 1996.
13. M. Herkenham, A. B. Lynn, M. R. Johnson, L. S.Melvin, B. R. de Costa, and K. C. Rice, "Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study," The Journal of Neuroscience, vol. 11, no. 2, pp. 563-583, 1991.
14. K. Tsou, S. Brown, M. C. Sañudo-Peña, K. Mackie, and J. M. Walker, "Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system," Neuroscience, vol. 83, no. 2, pp. 393-411, 1998.
15. M. Egertov, D. K. Giang, B. F. Cravatt, and M. R. Elphick, "A new perspective on cannabinoid signalling: Complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain," Proceedings of the Royal Society B, vol. 265, no. 1410, pp. 2081-2085, 1998.
16. R. I. Wilson and R. A. Nicoll, "Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses," Nature, vol. 410, no. 6828, pp. 588-592, 2001.
17. A. C. Howlett, F. Barth, T. I. Bonner, et al., "International Union of Pharmacology. XXVII. Classification of cannabinoid receptors," Pharmacological Reviews, vol. 54, no. 2, pp. 161-202, 2002.
18. A. Giuffrida, M. Beltramo, and D. Piomelli, "Mechanisms of endocannabinoid inactivation: Biochemistry and pharmacology," Journal of Pharmacology and Experimental Therapeutics, vol. 298, no. 1, pp. 7-14, 2001.
19. M. K. McKinney and B. E. Cravatt, "Structure and function of fatty acid amide hydrolase," Annual Review of Biochemistry, vol. 74, pp. 411-432, 2005.
20. P. Pacher, S. Bátkai, and G. Kunos, "The endocannabinoid system as an emerging target of pharmacotherapy," Pharmacological Reviews, vol. 58, no. 3, pp. 389-462, 2006.
21. A. J. Brown, "Novel cannabinoid receptors," British Journal of Pharmacology, vol. 152, no. 5, pp. 567-575, 2007.
22. M. R. Price, G. L. Baillie, A. Thomas, et al., "Allosteric modulation of the cannabinoid CB1 receptor," Molecular Pharmacology, vol. 68, no. 5, pp. 1484-1495, 2005.
23. M. D. Van Sickle, M. Duncan, P. J. Kingsley, et al., "Identification and functional characterization of brainstem cannabinoid CB2 receptors," Science, vol. 310, no. 5746, pp. 329-332, 2005.
24. J.-P. Gong, E. S. Onaivi,H. Ishiguro, et al., "Cannabinoid CB2 receptors: Immunohistochemical localization in rat brain," Brain Research, vol. 1071, no. 1, pp. 10-23, 2006.
25. M. P. Viveros, E. M. Marco, and S. E. File, "Endocannabinoid system and stress and anxiety responses," Pharmacology Biochemistry and Behavior, vol. 81, no. 2, pp. 331-342, 2005.
26. F. G. Grae., "Neuroanatomy and neurotransmitter regulation of defensive behaviours and related emotions in mammals," Brazilian Journal of Medical and Biological Research, vol. 27, no. 4, pp. 811-829, 1994.
27. N. McNaughton and J. A. Gray, "Anxiolytic action on the behavioural inhibition system implies multiple types of arousal contribute to anxiety," Journal of A.ective Disorders, vol. 61, no. 3, pp. 161-176, 2000.
28. N. McNaughton and P. J. Corr, "A two-dimensional neuropsychology of defense: Fear/anxiety and defensive distance," Neuroscience & Biobehavioral Reviews, vol. 28, no. 3, pp. 285-305, 2004.
29. R. Bandler, K. A. Keay, N. Floyd, and J. Price, "Central circuits mediating patterned autonomic activity during active vs. passive emotional coping," Brain Research Bulletin, vol. 53, no. 1, pp. 95-104, 2000.
30. R. Bandler and A. Depaulis, "Elicitation of intraspecific defence reactions in the rat from midbrain periaqueductal grey by microinjection of kainic acid, without neurotoxic effects," Neuroscience Letters, vol. 88, no. 3, pp. 291-296, 1988.
31. N. A. Patel, R. L. Moldow, J. A. Patel, G.-D. Wu, and S. L. Chang, "Arachidonylethanolamide (AEA) activation of FOS proto-oncogene protein immunoreactivity in the rat brain," Brain Research, vol. 797, no. 2, pp. 225-233, 1998.
32. C.-L. Chin, A. E. Tovcimak, V. P. Hradil, et al., "Di.erential effects of cannabinoid receptor agonists on regional brain activity using pharmacological MRI," British Journal of Pharmacology, vol. 153, no. 2, pp. 367-379, 2008.
33. W. J. Martin, S. L. Patrick, P. O. Coffin, K. Tsou, and J. M. Walker, "An examination of the central sites of action of cannabinoid-induced antinociception in the rat," Life Sciences, vol. 56, no. 23-24, pp. 2103-2109, 1995.
34. J. M. Walker, S. M. Huang, N. M. Strangman, K. Tsou, and M. C. Sañudo-Peña, "Pain modulation by release of the endogenous cannabinoid anandamide," Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 21, pp. 12198-12203, 1999.
35. A. G. Hohmann and R. L. Suplita II, "Endocannabinoid mechanisms of pain modulation," The AAPS Journal, vol. 8, no. 4, pp. E693-E708, 2006.
36. D. P. Finn, M. D. Jhaveri, S. R. G. Beckett, et al., "E.ects of direct periaqueductal grey administration of a cannabinoid receptor agonist on nociceptive and aversive responses in rats," Neuropharmacology, vol. 45, no. 5, pp. 594-604, 2003.
37. E. S. Onaivi, M. R. Green, and B. R. Martin, "Pharmacological characterization of cannabinoids in the elevated plus maze," Journal of Pharmacology and Experimental Therapeutics, vol. 253, no. 3, pp. 1002-1009, 1990.
38. E. Valjent, J. M. Mitchell, M.-J. Besson, J. Caboche, and R. Maldonado, "Behavioural and biochemical evidence for interactions between Δ9-tetrahydrocannabinol and nicotine," British Journal of Pharmacology, vol. 135, no. 2, pp. 564-578, 2002.
39. 9- tetrahydrocannabinol," Psychopharmacology, vol. 163, no. 1, pp. 111-117, 2002.
40. S. Patel and C. J. Hillard, "Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: Further evidence for an anxiolytic role for endogenous cannabinoid signalling," Journal of Pharmacology and Experimental Therapeutics, vol. 318, no. 1, pp. 304-311, 2006.
41. D. Braida, V. Limonta, L. Malabarba, A. Zani, and M. Sala, "5-HT1A receptors are involved in the anxiolytic e.ect of Δ9- tetrahydrocannabinol and AM 404, the anandamide transport inhibitor, in Sprague-Dawley rats," European Journal of Pharmacology, vol. 555, no. 2-3, pp. 156-163, 2007.
42. N. L. Schramm-Sapyta, Y. M. Cha, S. Chaudhry, W. A. Wilson, H. S. Swartzwelder, and C. M. Kuhn, "Di.erential anxiogenic, aversive, and locomotor effects of THC in adolescent and adult rats," Psychopharmacology, vol. 191, no. 4, pp. 867-877, 2007.
43. T. Rubino, M. Sala, D. Viganó, et al., "Cellular mechanisms underlying the anxiolytic effect of low doses of peripheral Δ9-tetrahydrocannabinol in rats," Neuropsychopharmacology, vol. 32, no. 9, pp. 2036-2045, 2007.
44. F. S. Guimarães, T. M. Chiaretti, F. G. Graeff, and A. W. Zuardi, "Antianxiety e.ect of cannabidiol in the elevated plus-maze," Psychopharmacology, vol. 100, no. 4, pp. 558-559, 1990.
45. F. S. Guimarães, J. C. de Aguiar, R. Mechoulam, and A. Breuer, "Anxiolytic e.ect of cannabidiol derivatives in the elevated plus-maze," General Pharmacology, vol. 25, no. 1, pp. 161-164, 1994.
46. F. A.Moreira, D. C. Aguiar, and F. S. Guimarães, "Anxiolyticlike effect of cannabidiol in the rat Vogel conflict test," Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 30, no. 8, pp. 1466-1471, 2006.
47. L. B. Resstel, S. R. L. Joca, F. A. Moreira, F. M. A. Corrêaa, and F. S. Guimarães, "Effects of cannabidiol and diazepam on behavioural and cardiovascular responses induced by contextual conditioned fear in rats," Behavioural Brain Research, vol. 172, no. 2, pp. 294-298, 2006.
48. D. Giuliani, F. Ferrari, and A. Ottani, "The cannabinoid agonistHU210 modifies rat behavioural responses to novelty and stress," Pharmacological Research, vol. 41, no. 1, pp. 45-51, 2000.
49. W. Jiang, Y. Zhang, L. Xiao, et al., "Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects," The Journal of Clinical Investigation, vol. 115, no. 11, pp. 3104-3116, 2005.
50. M. N. Hill and B. B. Gorzalka, "Enhancement of anxiety-like responsiveness to the cannabinoid CB1 receptor agonist HU- 210 following chronic stress," European Journal of Pharmacology, vol. 499, no. 3, pp. 291-295, 2004.
51. J. Haller, B. Varga, C. Ledent, and T. F. Freund, "CB1 cannabinoid receptors mediate anxiolytic effects: Convergent genetic and pharmacological evidence with CB1-specific agents," Behavioural Pharmacology, vol. 15, no. 4, pp. 299-304, 2004.
52. J. Haller, F. Mátyás, K. Soproni, et al., "Correlated species di.erences in the e.ects of cannabinoid ligands on anxiety and on GABAergic and glutamatergic synaptic transmission," European Journal of Neuroscience, vol. 25, no. 8, pp. 2445-2456, 2007.
53. C. Arévalo, R. de Miguel, and R. Hernández-Tristán, "Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters," Pharmacology Biochemistry and Behavior, vol. 70, no. 1, pp. 123-131, 2001.
54. S. Marín, E. Marco, M. Biscaia, et al., "Involvement of the κ- opioid receptor in the anxiogenic-like effect of CP 55,940 in male rats," Pharmacology Biochemistry and Behavior, vol. 74, no. 3, pp. 649-656, 2003.
55. E. M. Marco, L. Pérez-Alvarez, E. Borcel, et al., "Involvement of 5-HT1A receptors in behavioural e.ects of the cannabinoid receptor agonist CP 55,940 in male rats," Behavioural Pharmacology, vol. 15, no. 1, pp. 21-27, 2004.
56. R. F. Genn, S. Tucci, E. Marco, M.-P. Viveros, and S. E. File, "Anxiolytic and anxiogenic e.ects of the cannabinoid agonist CP 55,940 in animal tests of anxiety," Journal of Psychopharmacology, vol. 17, p. A27, 2003.
57. R. F. Genn, S. Tucci, E. M. Marco, M. P. Viveros, and S. E. File, "Unconditioned and conditioned anxiogenic effects of the cannabinoid receptor agonist CP 55,940 in the social interaction test," Pharmacology Biochemistry and Behavior, vol. 77, no. 3, pp. 567-573, 2004.
58. A. Chakrabarti, J. E. Ekuta, and E. S. Onaivi, "Neurobehavioral effects of anandamide and cannabinoid receptor gene expression in mice," Brain Research Bulletin, vol. 45, no. 1, pp. 67-74, 1998.
59. M. Scherma, J. Medalie, W. Fratta, et al., "The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition," Neuropharmacology, vol. 54, no. 1, pp. 129-140, 2008.
60. M. Bortolato, P. Campolongo, R. A. Mangieri, et al., "Anxiolytic-like properties of the anandamide transport inhibitor AM404," Neuropsychopharmacology, vol. 31, no. 12, pp. 2652-2659, 2006.
61. S. Kathuria, S. Gaetani, D. Fegley, et al., "Modulation of anxiety through blockade of anandamide hydrolysis," Nature Medicine, vol. 9, no. 1, pp. 76-81, 2003.
62. P. S. Naidu, S. A. Varvel, K. Ahn, B. F. Cravatt, B. R. Martin, and A. H. Lichtman, "Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality," Psychopharmacology, vol. 192, no. 1, pp. 61-70, 2007.
63. F. A. Moreira, N. Kaiser, K. Monory, and B. Lutz, "Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors," Neuropharmacology, vol. 54, no. 1, pp. 141-150, 2008.
64. M. Rutkowska, J. Jamontt, and H. Gliniak, "Effects of cannabinoids on the anxiety-like response in mice," Pharmacological Reports, vol. 58, no. 2, pp. 200-206, 2006.
65. M. Navarro, E. Hernández, R. M. Muñoz, et al., "Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat," NeuroReport, vol. 8, no. 2, pp. 491-496, 1997.
66. J. Haller, N. Bakos, M. Szirmay, C. Ledent, and T. F. Freund, "The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety," European Journal of Neuroscience, vol. 16, no. 7, pp. 1395-1398, 2002.
67. G. Griebel, J. Stemmelin, and B. Scatton, "Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents," Biological Psychiatry, vol. 57, no. 3, pp. 261-267, 2005.
68. R. J. Rodgers, P. M. Evans, and A. Murphy, "Anxiogenic profile of AM-251, a selective cannabinoid CB1 receptor antagonist, in plus-maze-naïve and plus-maze-experienced mice," Behavioural Pharmacology, vol. 16, no. 5-6, pp. 405-413, 2005.
69. J.W. Kasckow, J. J.Mulchahey, and T. D. Geracioti Jr., "Effects of the vanilloid agonist olvanil and antagonist capsazepine on rat behaviours," Progress in Neuropsychopharmacology and Biological Psychiatry, vol. 28, no. 2, pp. 291-295, 2004.
70. D. P. Finn, M. D. Jhaveri, S. R. G. Beckett, D. A. Kendall, C. A. Marsden, and V. Chapman, "Cannabinoids modulate ultrasound-induced aversive responses in rats," Psychopharmacology, vol. 172, no. 1, pp. 41-51, 2004.
71. F. A.Moreira, D. C. Aguiar, and F. S. Guimarães, "Anxiolyticlike effect of cannabinoids injected into the rat dorsolateral periaqueductal gray," Neuropharmacology, vol. 52, no. 3, pp. 958-965, 2007.
72. S. Pellow and S. E. File, "Anxiolytic and anxiogenic drug e.ects on exploratory activity in an elevated plus-maze: A novel test of anxiety in the rat," Pharmacology Biochemistry and Behavior, vol. 24, no. 3, pp. 525-529, 1986.
73. S. F. Lisboa, L. B. Resstel, D. C. Aguiar, and F. S. Guimarães, "Activation of cannabinoid CB1 receptors in the dorsolateral periaqueductal gray induces anxiolytic effects in rats submitted to the Vogel conflict test," European Journal of Pharmacology, vol. 593, no. 1-3, pp. 73-78, 2008.
74. J. R. Vogel, B. Beer, and D. E. Clody, "A simple and reliable conflict procedure for testing anti-anxiety agents," Psychopharmacologia, vol. 21, no. 1, pp. 1-7, 1971.
75. M. J. Millan, "The neurobiology and control of anxious states," Progress in Neurobiology, vol. 70, no. 2, pp. 83-244, 2003.
76. M.-P. Viveros, E.-M. Marco, R. Llorente, and M. López- Gallardo, "Endocannabinoid system and synaptic plasticity: Implications for emotional responses," Neural Plasticity, vol. 2007, Article ID 52908, 12 pages, 2007.
77. A. G. Hohmann, R. L. Suplita, N. M. Bolton, et al., "An endocannabinoid mechanism for stress-induced analgesia," Nature, vol. 435, no. 7045, pp. 1108-1112, 2005.
78. L. B. Resstel, S. F. Lisboa, D. C. Aguiar, F. M. A. Corrêa, and F. S. Guimarães, "Activation of CB1 cannabinoid receptors in the dorsolateral periaqueductal gray reduces the expression of contextual fear conditioning in rats," Psychopharmacology, vol. 198, no. 3, pp. 405-411, 2008.
79. M. S. Fanselow, "Conditional and unconditional components of post-shock freezing," The Pavlovian Journal of Biological Science, vol. 15, no. 4, pp. 177-182, 1980.
80. L. B. Resstel, S. R. Joca, F. G. Guimarães, and F. M. A. Corrêa, "Involvement of medial prefrontal cortex neurons in behavioural and cardiovascular responses to contextual fear conditioning," Neuroscience, vol. 143, no. 2, pp. 377-385, 2006.
81. P. Carrive, J. Lee, and A. Su, "Lidocaine blockade of amygdala output in fear-conditioned rats reduces Fos expression in the ventrolateral periaqueductal gray," Neuroscience, vol. 95, no. 4, pp. 1071-1080, 1999.
82. P. Carrive, P. Leung, J. Harris, and G. Paxinos, "Conditioned fear to context is associated with increased Fos expression in the caudal ventrolateral region of the midbrain periaqueductal gray," Neuroscience, vol. 78, no. 1, pp. 165-177, 1997.
83. P. Amorapanth, K. Nader, and J. E. LeDoux, "Lesions of periaqueductal gray dissociate-conditioned freezing from conditioned suppression behaviour in rats," Learning & Memory, vol. 6, no. 5, pp. 491-499, 1999.
84. J. E. LeDoux, J. Iwata, P. Cicchetti, and D. J. Reis, "Di.erent projections of the central amygdaloid nucleus mediate autonomic and behavioural correlates of conditioned fear," The Journal of Neuroscience, vol. 8, no. 7, pp. 2517-2529, 1988.
85. C. W. Vaughan, M. Connor, E. E. Bagley, and M. J. Christie, "Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro," Molecular Pharmacology, vol. 57, no. 2, pp. 288-295, 2000.
86. A. C. Campos and F. S. Guimarães, "Involvement of 5HT1A receptors in the anxiolytic-like e.ects of cannabidiol injected into the dorsolateral periaqueductal gray of rats," Psychopharmacology, vol. 199, no. 2, pp. 223-230, 2008.
87. A.L. Terzian, D.C. Aguiar, F.S. Guimarães, and F.A. Moreira, "Modulation of anxiety-like behaviour by Transient Receptor Potential Vanilloid Type 1 Channel (TRPV1) located in the dorsolateral periaqueductal gray," European Neuropsychopharmacology. In press.
88. N. S. Canteras, "The medial hypothalamic defensive system: hodological organization and functional implications," Pharmacology Biochemistry and Behavior, vol. 71, no. 3, pp. 481-491, 2002.
89. F. A. Moreira and B. Lutz, "The endocannabinoid system: Emotion, learning and addiction," Addiction Biology, vol. 13, no. 2, pp. 196-212, 2008.
90. A. W. Zuardi, I. Shirakawa, E. Finkelfarb, and I. G. Karniol, "Action of cannabidiol on the anxiety and other e.ects produced by Δ9-THC in normal subjects," Psychopharmacology, vol. 76, no. 3, pp. 245-250, 1982.
91. A.W. Zuardi, J. A. S. Crippa, J. E. C.Hallak, F. A.Moreira, and F. S. Guimarães, "Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug," Brazilian Journal of Medical and Biological Research, vol. 39, no. 4, pp. 421-429, 2006.
92. A.W. Zuardi, R. A. Cosme, F. G. Grae., and F. S. Guimarães, "E.ects of ipsapirone and cannabidiol on human experimental anxiety," Journal of Psychopharmacology, vol. 7, no. 1, pp. 82-88, 1993.
93. J. A. de Souza Crippa, A. W. Zuardi, G. E. J. Garrido, et al., "E.ects of cannabidiol (CBD) on regional cerebral blood flow," Neuropsychopharmacology, vol. 29, no. 2, pp. 417-426, 2004.
94. T. Bisogno, L. Hanuš, L. De Petrocellis, et al., "Molecular targets for cannabidiol and its synthetic analogues: E.ect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide," British Journal of Pharmacology, vol. 134, no. 4, pp. 845-852, 2001.
95. E. B. Russo, A. Burnett, B. Hall, and K. K. Parker, "Agonistic properties of cannabidiol at 5-HT1a receptors," Neurochemical Research, vol. 30, no. 8, pp. 1037-1043, 2005.
96. L. Cristino, L. de Petrocellis, G. Pryce, D. Baker, V. Guglielmotti, and V. Di Marzo, "Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain," Neuroscience, vol. 139, no. 4, pp. 1405-1415, 2006.
97. R. L. Nogueira and F. G. Grae., "Role of 5-HT receptor subtypes in the modulation of dorsal periaqueductal gray generated aversion," Pharmacology Biochemistry and Behavior, vol. 52, no. 1, pp. 1-6, 1995.
98. J. R. Raymond, Y. V. Mukhin, T. W. Gettys, and M. N. Garnovskaya, "The recombinant 5-HT1A receptor: G protein coupling and signalling pathways," British Journal of Pharmacology, vol. 127, no. 8, pp. 1751-1764, 1999.
99. G. A. Carrasco and L. D. Van de Kar, "Neuroendocrine pharmacology of stress," European Journal of Pharmacology, vol. 463, no. 1-3, pp. 235-272, 2003.
100. J. M. Zanoveli, R. L. Nogueira, and H. Zangrossi Jr., "vvSerotonin in the dorsal periaqueductal gray modulates inhibitory avoidance and one-way escape behaviours in the elevated T-maze," European Journal of Pharmacology, vol. 473, no. 2-3, pp. 153-161, 2003.
101. V. de Paula Soares and H. Zangrossi Jr., "Involvement of 5- HT1A and 5-HT2 receptors of the dorsal periaqueductal gray in the regulation of the defensive behaviours generated by the elevated T-maze," Brain Research Bulletin, vol. 64, no. 2, pp. 181-188, 2004.
102. M. J. Caterina,M. A. Schumacher, M. Tominaga, T. A. Rosen, J. D. Levine, and D. Julius, "The capsaicin receptor: A heatactivated ion channel in the pain pathway," Nature, vol. 389, no. 6653, pp. 816-824, 1997.
103. A. Szallasi and P. M. Blumberg, "Vanilloid (Capsaicin) receptors and mechanisms," Pharmacology Reviews, vol. 51, no. 2, pp. 159-212, 1999.
104. M. van der Stelt and V. Di Marzo, "Endovanilloids: Putative endogenous ligands of transient receptor potential vanilloid 1 channels," European Journal of Biochemistry, vol. 271, no. 10, pp. 1827-1834, 2004.
105. S. Marinelli, V. Di Marzo, F. Florenzano, et al., "Narachidonoyl- dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors," Neuropsychopharmacology, vol. 32, no. 2, pp. 298-308, 2007.
106. É. Mezey, Z. E. Tóth, D. N. Cortright, et al., "Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human," Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 7, pp. 3655-3660, 2000.
107. S. McGaraughty, K. L. Chu, R. S. Bitner, et al., "Capsaicin infused into the PAG a.ects rat tail flick responses to noxious heat and alters neuronal firing in the RVM," Journal of Neurophysiology, vol. 90, no. 4, pp. 2702-2710, 2003.
108. E. Palazzo, V. de Novellis, I. Marabese, et al., "Interaction between vanilloid and glutamate receptors in the central modulation of nociception," European Journal of Pharmacology, vol. 439, no. 1-3, pp. 69-75, 2002.
109. J. Xing and J. Li, "TRPV1 receptor mediates glutamatergic synaptic input to dorsolateral periaqueductal gray (dl-PAG) neurons," Journal of Neurophysiology, vol. 97, no. 1, pp. 503-511, 2007.
110. M. L. Molchanov and F. S. Guimarães, "Anxiolytic-like e.ects of AP7 injected into the dorsolateral or ventrolateral columns of the periaqueductal gray of rats," Psychopharmacology, vol. 160, no. 1, pp. 30-38, 2002.
111. R. Marsch, E. Foeller, G. Rammes, et al., "Reduced anxiety, conditioned fear, and hippocampal long-term potentiation in transient receptor potential vanilloid type 1 receptordeficient mice," The Journal of Neuroscience, vol. 27, no. pp. 832-839, 2007.
112. V.Micale, L. Cristino, A. Tamburella, et al., "Anxiolytic e in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels," Neuropsychopharmacology. In press.
113. T. Rubino, N. Realini, C. Castiglioni, et al., "Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex," Cerebral Cortex, vol. 18, no. 6, pp. 292-301, 2008.
114. T. Rubino, C. Guidali, D. Vigano, et al., "CB1 receptor stimulation in specific brain areas di.erently modulate anxiety-related behaviour," Neuropharmacology, vol. 54, 1, pp. 151-160, 2008.
115. E. S. Onaivi, A. Chakrabarti, E. T. Gwebu, and G. Chaudhuri, "Neurobehavioral e.ects of Δ9-THC and cannabinoid (CB1) receptor gene expression in mice," Behavioural Research, vol. 72, no. 1-2, pp. 115-125, 1996.